CA-XSOLLA
16.12.2021 06:05:07 CET | Business Wire | Press release
Xsolla, the world's leading video game commerce company, continues opening doors to more revenue opportunities for mobile game developers. Based on recent changes to Apple’s rules for the App Store, developers are now able to gather player contact information and use that information to contact those players to process payments outside of in-app purchases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005807/en/
Xsolla Web Shop is precisely built for this purpose and empowers mobile game developers to create a shop on their own website. Using the Web Shop, players can purchase in-game items, virtual currencies, subscriptions, top up player accounts, and more, all for only 5% per transaction. That represents huge operational savings over traditional in-app payment options and keeps more revenue in the developer's pocket. Furthermore, Xsolla Web Shop is a white label store on a developer’s own, branded website that accepts 700+ local payment options. This makes it simple for players to make purchases directly with their payment of choice. No pyramid scheme here; players stay with the developer.
Web Shop doesn’t require complicated back-end coding or extensive design work, and developers can get started immediately. The simple integration steps are outlined in Xsolla’s latest blog post . Once a web shop is live, developers can inform their players about the opportunity to make purchases online through several communication methods such as email, social media, newsletters, Discord servers, and more. See a demonstration of the Web Shop here .
“Xsolla anticipated this seismic shift earlier this year when we launched multiple products actively used by some of the world’s largest game companies,” said Chris Hewish, President of Xsolla. “We’ve now combined these products and learnings into an elegant new solution called Xsolla Web Shop for Mobile Games, designed to increase revenue for developers and help them build closer relationships with their players.”
For more information about Xsolla Web Shop, visit https://xsolla.pro/web-shop . Xsolla also provides a free ebook with further details, available here: https://xsolla.pub/web-shop-ebook
About Xsolla
Xsolla is the world's leading video game commerce company, with a robust and powerful set of tools and services designed specifically for the games industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes to promote and monetize their games globally and across multiple platforms. As an innovative leader in mobile game commerce, Xsolla continues to solve the inherent complexities of global distribution, marketing, and monetization so their partners can grow audience, engagement, and revenue. With offices worldwide, Xsolla currently works with major gaming entities like Valve, Twitch, Roblox, Ubisoft, Epic Games, KRAFTON, NetEase, Nexters, Playstudios, Playrix, miHoYo, and more. For more information, please visit xsolla.com.
Web: www.xsolla.com
Email: business@xsolla.com
Facebook: https://www.facebook.com/xsolla.inc
Instagram: https://www.instagram.com/xsolla/
LinkedIn: https://www.linkedin.com/company/xsolla
Twitter: https://twitter.com/xsolla
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005807/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom